<DOC>
	<DOCNO>NCT02240875</DOCNO>
	<brief_summary>The purpose study assess two new Ebola vaccine : cAd3-EBO Z 3 different dos , second vaccine , MVA-BN® Filo , 3 different dos . The study enable u assess safety vaccine extent immune response healthy volunteer . The investigator give volunteer either one two vaccination , blood saliva test collect information symptom occur vaccination . This first trial use either vaccine human . We plan recruit total 92 volunteer vaccinate .</brief_summary>
	<brief_title>A Study Assess New Ebola Vaccines , cAd3-EBO Z MVA-BN® Filo</brief_title>
	<detailed_description>Long- term immunology follow-up : In order ass durability vaccine induce immunogenicity , vaccinated subject invite back attend maximum 3 optional follow visit least 12 month final vaccination . The 3 visit minimum interval 3 month , final visit must take place longer 12 month first optional visit . Volunteers attend visit ask occurrence SAEs intervening period . SAE data period collect volunteer decline attend additional visit .</detailed_description>
	<mesh_term>Hemorrhagic Fever , Ebola</mesh_term>
	<criteria>Healthy adult age 18 50 year Able willing ( Investigator 's opinion ) comply study requirement Willing allow investigator discuss volunteer 's medical history general practitioner ( GP ) For female , willingness practice continuous effective contraception study negative pregnancy test day ( ) screen vaccination Agreement refrain blood donation course study Provide write informed consent Participation another research study involve receipt investigational product 30 day precede enrolment , plan use study period Prior receipt investigational Ebola Marburg vaccine , chimpanzee adenovirus vectored vaccine investigational vaccine likely impact interpretation trial data Receipt live , attenuated vaccine within 28 day prior enrolment Receipt subunit kill vaccine within 14 day prior enrolment Administration immunoglobulins and/or blood product within three month precede plan administration vaccine candidate Any confirm suspected immunosuppressive immunodeficient state , include HIV infection ; asplenia ; recurrent , severe infection chronic ( 14 day ) immunosuppressant medication within past 6 month ( inhaled topical steroid allow ) History allergic disease reaction likely exacerbate component vaccine , ( e.g . egg product ) include urticaria , respiratory difficulty abdominal pain Any history hereditary angioedema , acquire angioedema , idiopathic angioedema . Any history anaphylaxis reaction vaccination Pregnancy , lactation willingness/intention become pregnant study History cancer ( except basal cell carcinoma skin cervical carcinoma situ ) History serious psychiatric condition Poorly control asthma thyroid disease Seizure past 3 year treatment seizure disorder past 3 year Bleeding disorder ( eg . Factor deficiency , coagulopathy platelet disorder ) , prior history significant bleed bruise follow intramuscular injection venepuncture Any serious chronic illness require hospital specialist supervision Current antituberculosis prophylaxis therapy Suspected know current alcohol abuse define alcohol intake great 42 unit every week Suspected known inject drug abuse 5 year precede enrolment Seropositive hepatitis B surface antigen ( HBsAg ) Seropositive hepatitis C virus ( antibody HCV ) Travel Ebola Marburg endemic region study period within previous six month Any clinically significant abnormal find screen biochemistry haematology blood test urinalysis ( see Appendix A Appendix B ) Any significant disease , disorder finding may significantly increase risk volunteer participation study , affect ability volunteer participate study impair interpretation study data Inability study team contact volunteer 's GP confirm medical history safety participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Ebola</keyword>
	<keyword>Zaire</keyword>
</DOC>